NewsBenzingaEvommune presentará los resultados del estudio de fase 2a de EVO301 en dermatitis atópica moderada a grave en el Congreso de la Academia Europea de Dermatología y Venereología. Evommune presentará los resultados del estudio de fase 2a de EVO301 en dermatitis atópica moderada a grave en el Congreso de la Academia Europea de Dermatología y Venereología. Benzinga 2026.09.23 20:06 (GMT+0) Open on Benzinga Other news Billionaires Walk Away From Alphabet in Q3 - Hedge Funds Google ‘How to Sell’ and Hit Enter $100 Invested In Visa 15 Years Ago Would Be Worth This Much Today Western Digital Gains, Seagate Flat As Nvidia’s Raised Outlook Lifts AI Storage Hopes Home Depot Posts Strongest Comps In 4 Years, Analysts Revise Price Targets TJ Maxx Parent Bets on Accelerating Sales This Holiday Season Why Is Coinbase Stock Falling on Wednesday?